Headquartered in Vancouver, BC Fiscal year ends December NASDAQ: ABCL abcellera.com
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines. The company operates across therapeutic areas including endocrinology, women's health, immunology, and oncology. AbCellera's business model combines an internal proprietary drug pipeline with a technology platform that enables partnerships with pharmaceutical companies. Its T-cell engager (TCE) platform provides end-to-end capabilities from discovery to manufacturing. The company generates revenue through research fees from partner collaborations and licensing/royalty payments tied to downstream program milestones. AbCellera maintains a portfolio of partner-led programs with downstream economic stakes and is advancing multiple internal clinical candidates including ABCL635 (Phase 2), ABCL575 (Phase 1), and earlier-stage programs ABCL386 and ABCL688. Updated
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product…
Penny stocks represent an interesting investment opportunity. These stocks typically represent small companies or companies that are early in the development stages. But isn’t that how you make it big in the…
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines. The company operates across therapeutic areas including endocrinology, women's health, immunology, and oncology.
The Wall Street consensus 12-month price target for ABCL is $16.70.
